Massive Shrimp Recall: Nearly 45,000 Pounds Affected Over Dangerous Listeria Risk
The frozen product was distributed directly to distributors and retailers in California, Oregon, Washington, and British Columbia in Canada. Per the FDA, the product may have been further distributed and sold at retailers nationwide.
The recalled item is packaged in 1- and 5-pound plastic bags under the Bornstein Seafoods brand. The lot code is printed in the lower-left corner of the master case labels and at the bottom on the backs of the bags.
The affected 1-pound bags of shrimp meat have the UPC code 614133200246 and lot numbers A19008, A19009, A19019, A19026, A19030, A19032, A19037, and A19039. The affected 5-pound bags have the UPC code 614133200239 and lot numbers A19009, P11710, A18989, A19006, A19007, P11709, and P11710.
During routine sampling, listeria was detected in an in-process shrimp sample in the food production environment. Bornstein Seafoods has stopped distributing the product as it investigates what caused the problem.
Listeria monocytogenes is an organism that can cause serious and sometimes fatal infections in young children, elderly people, and others with weakened immune systems. According to the U.S. Centers for Disease Control and Prevention (CDC), symptoms of an intestinal illness caused by listeria typically include diarrhea and vomiting. Symptoms usually start within 24 hours after consuming the contaminated food and last one to three days.
If the bacteria has spread beyond the gut, people may experience more serious symptoms such as high fever, severe headache, stiffness, muscle aches, and fatigue. Symptoms of this type of illness usually start within two weeks after eating the contaminated food.
If you have a fever and other symptoms of listeriosis, such as fatigue and muscle aches, contact your healthcare provider immediately. So far, no illnesses have been reported due to the recalled product.
If you purchased the recalled product, return it to the place of purchase for a full refund. Consumers with questions may contact Bornstein Seafoods by emailing Andrew@bornstein.com.
Read the original article on Martha Stewart
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, acknowledges that the Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the conditional marketing authorization (CMA) for ELEVIDYS (delandistrogene moxeparvovec) in ambulatory individuals ages three to seven years for the treatment of Duchenne muscular dystrophy (DMD). 'While we are disappointed by the CHMP's negative opinion, we understand the urgent need for continued dialogue and collaboration to bring transformative therapies to people with Duchenne who live with a relentless disease that steals their mobility, independence and ultimately life – often by early adulthood," said Louise Rodino-Klapac, Ph.D., president of research & development and technical operations, Sarepta. 'Following the initial FDA approval of ELEVIDYS on June 22, 2023, the therapy has subsequently received regulatory approval in several other countries. In the U.S., we are actively working with the FDA to address recent safety questions. We remain committed to working with regulators to address outstanding questions on safety so that people living with Duchenne have access to this important therapy.' ELEVIDYS is the first and only approved gene therapy targeting the underlying cause of disease that has consistently demonstrated stabilization or slowing of DMD disease progression, with durable effects on functional and biological outcomes and muscle health. While the primary endpoint was not met in EMBARK after one year, ELEVIDYS showed clinically meaningful and statistically significant improvements across important secondary endpoints of functional outcome measures when compared to placebo. Longer term efficacy data were also submitted to EMA, including two-year results from the EMBARK study and three-year pooled efficacy analysis from three other ELEVIDYS studies that showed clinically meaningful improvements across key measures of motor function. One-year data from part one of the EMBARK study were published in Nature Medicine in October 2024, and results from year two were shared at this year's Muscular Dystrophy Association Clinical & Scientific Conference in Dallas. Quantitative muscle MR (magnetic resonance) outcomes from part 1 of EMBARK were published in JAMA Neurology in May 2025. Sarepta is responsible for regulatory approval and commercialization of ELEVIDYS in the U.S., as well as manufacturing. Roche is responsible for regulatory approvals and bringing ELEVIDYS to patients across the rest of the world. Regulatory approval and commercialization of ELEVIDYS in Japan is through Chugai Pharmaceuticals via its alliance with Roche. About ELEVIDYS (delandistrogene moxeparvovec-rokl) ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS is indicated in U.S. for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in the DMD gene For patients who are non-ambulatory and have a confirmed mutation in the DMD gene. The DMD indication in non-ambulatory patients is approved under accelerated approval in the U.S. based on expression of ELEVIDYS micro-dystrophin (noted hereafter as 'micro-dystrophin') in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). U.S. IMPORTANT SAFETY INFORMATION CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. WARNINGS AND PRECAUTIONS: Infusion-related Reactions: Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during administration and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow, or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate. ELEVIDYS should be administered in a setting where treatment for infusion-related reactions is immediately available. Discontinue infusion for anaphylaxis. Acute Serious Liver Injury: Acute serious liver injury has been observed with ELEVIDYS, and administration may result in elevations of liver enzymes (such as GGT, GLDH, ALT, AST) or total bilirubin, typically seen within 8 weeks. Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled. Prior to ELEVIDYS administration, perform liver enzyme test and monitor liver function (clinical exam, GGT, and total bilirubin) weekly for the first 3 months following ELEVIDYS infusion. Continue monitoring if clinically indicated, until results are unremarkable (normal clinical exam, GGT, and total bilirubin levels return to near baseline levels). Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated. If acute serious liver injury is suspected, consultation with a specialist is recommended. Immune-mediated Myositis: In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms of severe muscle weakness, including dysphagia, dyspnea, and hypophonia, were observed. Limited data are available for ELEVIDYS treatment in patients with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction. Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [e.g., calcineurin-inhibitor] in addition to corticosteroids) based on patient's clinical presentation and medical history if these symptoms occur. Myocarditis: Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials. If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes. Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath. Advise patients to contact a physician immediately if they experience cardiac symptoms. Preexisting Immunity against AAVrh74: In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies. Perform baseline testing for presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration. ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers greater than or equal to 1:400. Adverse Reactions: The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, and thrombocytopenia. Report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782). For further information, please see the full Prescribing Information. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and limb-girdle muscular dystrophies (LGMDs) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Internet Posting of Information We routinely post information that may be important to investors in the 'For Investors' section of our website at We encourage investors and potential investors to consult our website regularly for important information about us. Forward-Looking Statements This statement contains 'forward-looking statements.' Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as 'will,' 'may,' 'potential' and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, research and development programs, discussions with regulators and the prospects for approvals or continued approvals, as applicable, of ELEVIDYS and the potential benefits and risks of ELEVIDYS. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: different methodologies, assumptions and applications we use to assess particular safety or efficacy parameters may yield different statistical results; our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences; the possible impact of regulatory decisions by, and any halts imposed by, regulatory agencies on our business; and those risks identified under the heading 'Risk Factors' in our most recent Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review. Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained herein. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law. Source: Sarepta Therapeutics, Inc.
Fox News
an hour ago
- Fox News
FDA chief has no 'plans' for abortion pill policy changes but continues safety review
Food and Drug Administration Commissioner Marty Makary said in a recent interview he has "no preconceived plans" to modify policies surrounding abortion pill mifepristone, which is designed to end a pregnancy in the first 10 weeks. "We have an ongoing review of safety data on mifepristone, which is a requirement from the prior administrations," Makary said in an interview with POLITICO. "You always have to be open-minded. You have to listen to different opinions and make decisions based on what you think is the right thing to do." His comments mirror those he made during the Semafor World Economy Summit in April. During the summit, Makary said he has "no plans to take action" that would restrict the abortion drug's availability, but cautioned the agency wouldn't hesitate to act if the data suggested there was a safety issue. "There is an ongoing set of data that is coming into the FDA on mifepristone," he said. "So if the data suggests something or tells us that there's a real signal, we can't promise we're not going to act on that data." Sen. Josh Hawley, R-Mo., wrote an April 28 letter to Makary regarding safety concerns about mifepristone. "I urge you to follow this new data and take all appropriate action to restore critical safeguards on the use of mifepristone. The health and safety of American women depend on it," Hawley wrote. Makary said during the interview with POLITICO that he has no plans to make "any changes" with policy regarding mifepristone, adding he would "continue to listen to folks that say they have concerns." Fox News Digital reached out to the FDA and Sen. Hawley for comment.
Yahoo
an hour ago
- Yahoo
This Low-Calorie Sugar Alternative May Support Weight Management, Experts Say
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." You've got your pick of alternatives if you're trying to cut back on sugar but still want to indulge your sweet tooth. There's a buzzy option that keeps popping up on ingredient labels that's gained attention on social media over the past few years. It's sweet and has the exact texture of regular table sugar, but here's the best part: allulose is technically not an artificial sweetener. Allulose is a sugar that shows up naturally in sweet foods like figs, raisins, maple syrup, and more, according to the Food and Drug Administration (FDA). But it's also commercially processed—it's found in a ton of low-sugar and low-calorie foods, such as protein bars, low-sugar cereals, and low-sugar yogurts, and you can also buy it in bags and pouches. Meet the experts: Scott Keatley, RD, is the co-owner of Keatley Medical Nutrition Therapy. Yasi Ansari, RDN, is a senior dietitian at UCLA Health Santa Monica. Antonette Hardie, RDN, is a registered dietitian at The Ohio State University Wexner Medical Center. Julie Upton, RD, is a San Francisco Bay Area-based registered dietitian. It's often hailed as a healthy alternative to table sugar (sucrose) because it 'tastes like sugar, looks like sugar, but provides almost no calories,' says Scott Keatley, RD, co-owner of Keatley Medical Nutrition Therapy. 'It provides bulk and browning in recipes, which lets it replace sugar without losing texture or flavor,' Keatley adds. And it may not spike your blood sugar as much as table sugar. Wondering if you should make the switch from table sugar to allulose? Ahead, find out the benefits and side effects of the alternative, and who should try it, per dietitians. Benefits Of Allulose There's some preliminary studies on allulose, but many of them have been conducted on animals, so it's hard to say for sure whether the benefits apply to people. It may regulate blood sugar. Allulose may help with blood sugar regulation in people with type 2 diabetes, says Yasi Ansari, RDN, senior dietitian at UCLA Health Santa Monica. Why? Allulose has a 'near-zero' glycemic index, which means it's unlikely to spike your blood sugar, Keatley explains. A 2024 Metabolism Open meta-analysis of clinical trials of the effect of allulose on blood glucose in people with type 2 diabetes found that those who consumed allulose had a 'significant reduction' in blood sugar levels after eating and drinking. Allulose may be worth swapping for table sugar in people with type 2 diabetes, but more research is needed to track allulose's long-term impact on blood sugar, according to the meta-analysis. It may support weight management. Depending how much table sugar you typically consume, swapping in allulose for your go-to sweetener could help you cut back on calories—as long as you're still in a calorie deficit overall, says Antonette Hardie, RDN, a registered dietitian at The Ohio State University Wexner Medical Center. Just a quick comparison: There are 48 calories in one tablespoon of table sugar, and 0 calories in one tablespoon of allulose. There is some research to suggest that allulose may help to increase fat loss, although it's not robust. A 2024 study in Nutrients involved feeding obese rats that had type 2 diabetes lab food with either stevia or allulose for 12 weeks to learn about the effects of allulose on the body. The rats who consumed allulose ate less food and gained less weight than those that ate stevia. As a result, the researchers concluded that allulose may be a good substitute for sugar—at least in rats managing obesity and type 2 diabetes. But research in humans is still in early stages, Keatley says. One 2018 study in Nutrients had 121 overweight or obese people consume a drink with either sucralose or allulose twice a day over 12 weeks. The researchers found that people in the allulose group lost more fat mass during the study period compared to those in the sucralose group. It may help protect against non-alcoholic fatty liver disease. Non-alcoholic fatty liver disease is a buildup of fat in the liver (not caused by alcohol use). If untreated, it can progress to inflammation and liver damage, Keatley explains. In animal studies, allulose has been shown to help reduce fat accumulation in the liver that can contribute to non-alcoholic fatty liver disease. Additionally, a small 2020 J-Stage study looked at 90 people who were given daily drinks with 15 grams, five grams, or zero grams (the placebo) of allulose over 48 weeks. It found that there were 'significant improvements' in markers linked with non-alcoholic fatty liver disease in the allulose groups. Transform your body composition with our exclusive strength training plan But the potential perks of allulose, especially in humans, are still being explored. 'While early findings are promising, we need more long-term human studies with larger and more diverse participant groups to make definitive recommendations, as current research remains limited,' says Ansari. Side Effects Of Allulose Allulose has been labeled by the FDA as Generally Recognized As Safe (or GRAS) which means it's considered safe to use like table sugar. However, just like with normal sugar, you may experience side effects like bloating or gas from consuming any amount of allulose, says Julie Upton, RD, a San Francisco Bay Area-based registered dietitian. 'Generally, if you enjoy a moderate amount of allulose, you will have minimal side effects,' she says. But if you consume a substantial amount in one sitting—like above 25 to 30 grams, or more than a tablespoon—Keatley says you may experience gastrointestinal side effects such as: Bloating Gas Loose stools Mild abdominal pain 'These symptoms occur because allulose isn't fully absorbed and ferments in the colon,' says Keatley. However, people usually build up a tolerance to allulose over time, so while you may experience gas the first time you eat it, that doesn't mean it'll be an issue down the road. Who Should (And Shouldn't) Eat Allulose Keatley says there are a lot of people who may benefit from eating allulose compared to normal sugar, such as those: With type 2 diabetes or prediabetes that want to manage their blood sugar Trying to lose weight who are struggling with sugar cravings Who are looking for a low-calorie sugar substitute But because allulose can cause GI issues, it's probably best to avoid for people with a sensitive digestive system or a history of GI concerns like irritable bowel syndrome (IBS), Ansari says. If the idea of using a low-calorie sweetener that tastes and feels like table sugar sounds like a dream, dietitians say you should go for it. Just start slow and see how you feel. 'Monitor how much you consume, what you consume allulose with, and how your body responds,' Ansari says. You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals
